On March 27, 2026, Editas Medicine, Inc. (NASDAQ: EDIT) announced that the U.S. Patent and Trademark Office (USPTO) has reaffirmed the Patent Trial and Appeal Board's (PTAB) previous decision favoring the Broad Institute in a significant patent interference case concerning CRISPR/Cas9 technology. This decision involves patents related to CRISPR/Cas9 editing in human cells, which are crucial for the ongoing development of gene editing therapies. The case involves a dispute between the Broad Institute, Massachusetts Institute of Technology (MIT), and Harvard University against the University of California, the University of Vienna, and Emmanuelle Charpentier, collectively known as CVC. The PTAB's ruling is the third consecutive decision affirming the Broad Institute's inventorship priority for CRISPR/Cas9 technology. This ruling comes after a remand from the U.S. Court of Appeals for the Federal Circuit, which had previously affirmed in part and vacated in part the PTAB's earlier decision. CVC retains the right to appeal this latest decision to the Federal Circuit. Gilmore O'Neill, President and CEO of Editas Medicine, expressed satisfaction with the decision, emphasizing the company's confidence in its intellectual property as it continues to leverage CRISPR technology to develop transformative medicines for serious diseases. Editas is currently advancing its experimental therapy, EDIT-401, which has shown promising results in reducing LDL cholesterol levels in non-human primates. The patents at issue are exclusively licensed to Editas for the development and commercialization of CRISPR/Cas9-based therapies, while other related patents remain unaffected by this decision. This reaffirmation of patent rights is expected to bolster Editas's position in the competitive gene editing landscape, potentially enhancing its market value and investor confidence.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.